Perhaps sales revenue relates to contracts signed and cash receipts is when the money has been received. In the last quarterly the cash receipts were slightly greater than sales revenue.
I'm optimistic of the prospects of the STI kit, especially considering it screens for the more pathogenic variant of chlamydia, and its a great sign they have customers for it already. I think one of the large Australian labs is using their enteric kit, so if they adopt the STI one as well, this will be a decent boost to revenue. It would be interesting to know what our sales OS are currently, but they haven't mentioned this. I hope we hear in the full year report.
Yes, I also noticed the price drop into the 30's before happened after similar peculiar small orders. I'll see if I can't take advantage by buying some more!
GSS Price at posting:
36.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)